Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma
Oncotarget2016Vol. 7(31), pp. 50624–50634
Citations Over Time
Yun Fan, Youhua Jiang, Xinming Zhou, Qixun Chen, Zhiyu Huang, Yanjun Xu, Lei Gong, Haifeng Yu, Haiyan Yang, Jinshi Liu, Tao Lei, Qiang Zhao, Weimin Mao
Abstract
Weekly nab-paclitaxel with three-weekly cisplatin seems effective and safe as a neoadjuvant chemotherapy strategy for locally advanced ESCC. Down-staged patients have favorable outcome.ClinicalTrials.gov Identifier: NCT01258192.
Related Papers
- → A Cost and Benefit Study of Esophagectomy for Patients with Esophageal Cancer(2009)3 cited
- → Will Patients With Resectable Esophageal Cancer Be Spared Esophagectomy?(2019)1 cited
- An appropriate esophagectomy for esophageal cancer: a lack of evidence and a growing disparity between Western and Eastern standards.(2006)
- → Evaluation of the Associated Factors with Weight Loss in Esophageal Cancer Patients Undergoing Esophagectomy(2011)
- → Effect of en bloc esophagectomy and total meso-esophagectomy on esophageal cancer patients: a systematic review and meta-analysis(2022)